Feasibility of sentinel lymph node biopsy omission after integration of (18)F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial

OBJECTIVE: Sentinel lymph node biopsy (SLNB) is currently the standard of care in clinically node negative (cN0) breast cancer. The present study aimed to evaluate the negative predictive value (NPV) of (18)F-FDG dedicated lymph node positron emission tomography (LymphPET) in cN0 patients. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Junjie, Cheng, Jingyi, Liu, Guangyu, Hou, Yifeng, Di, Genghong, Yang, Benglong, Jiang, Yizhou, Huang, Liang, Qu, Feilin, Chen, Sheng, Wang, Yan, Yu, Keda, Shao, Zhimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334763/
http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334763/
http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0085

Ejemplares similares